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Background: The transforming growth factor-β1 (TGF-β1) gene -509C/T
polymorphism has been suggested to be associated with increased coronary artery
disease (CAD) risk. However, the individual studies results are still inconsistent.
Objective and methods: To investigate the relationship between TGF-β1
gene -509C/T polymorphism and CAD, a meta-analysis involving 11,701 participants
from 8 individual studies was conducted. The pooled odds ratios (ORs) and their
corresponding 95% confidence intervals were evaluated by using random or fixed effect
models.
Results: A significant association between TGF-β1 gene -509C/T polymorphism and
CAD was detected in the total population under allelic (OR: 1.130, 95% CI: 1.060–1.200,
P = 0.0001), recessive (OR: 1.390, 95% CI: 1.100–1.750, P = 0.006), dominant (OR:
0.857, 95% CI: 0.785–0.935, P = 2.507 × 10−4), homozygous (OR: 1.258, 95% CI:
1.098–1.442, P = 0.001), heterozygous (OR: 1.147, 95% CI: 1.046–1.257, P = 0.003),
and additive genetic models (OR: 1.131, 95% CI: 1.063–1.204, P = 5.442 × 10−5).
In the subgroup analysis, there was a significant association between them in Chinese
population under all of the genetic models (P < 0.05), except under the heterozygous
genetic model (P > 0.05). In the Caucasian subgroup, a significant association between
them was also detected under all of the genetic models (P < 0.05), except under the
recessive genetic model (P > 0.05).
Conclusions: TGF-β1 gene -509C/T polymorphism was significantly associated with
increased CAD risk. The people with T allele of TGF-β1 gene -509C/T polymorphism
might be predisposed to CAD.
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INTRODUCTION
The coronary artery disease (CAD) morbidity rose markedly which presented a rejumvanation
trend (Zou et al., 2013). According to the mortality and disability rate, CAD is the most important
disease in the United States of America (USA) and other industrialized countries. In the nearly
one million patients who died of the cardiovascular disease in USA every year, CAD accounted
for 50%. About 1.5 million USA patients were attacked by acute myocardial infarction which was
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almost caused by coronary atherosclerosis (Yang et al., 2006).
CAD is the myocardial ischemia or necrosis disease caused by
the artery lumen stenosis due to the coronary atherosclerosis.
The CAD pathogenesis might be the combined actions result
by heredity and environmental factors. The single nucleotide
polymorphism is the important genetic factor which influences
the CAD susceptibility.
The human transforming growth factor-β1 (TGF-β1) gene,
located in 19q13 chromosome, spans 2.5 kb which consists
of 7 exons and 6 introns. The researches have confirmed
that TGF-β1 could increase the extracellular matrix, inhibit
the vascular smooth muscle cells proliferation, promote the
vascular endothelial cells, and regulate the local inflammation.
Thus TGF-β1 could influence the CAD progress (Aihara et al.,
2010). The -509C/T (rs1800469) mutation, located in the
upstream of the TGF-β1 gene transcriptional initiation site, is
the negative regulation region. C/T mutation alters the affinity
of the promoter and transcription factor which cause the
reduced TGF-β1 transcription level and participate in the CAD
progression (Yokota et al., 2000).
Although many studies on the relationship between TGF-β1
gene -509C/T polymorphism and CAD have been performed so
far, the individual studies results were still conflicting. In 2014,
Pei et al. found the TT genotype of the TGF-β1 gene -509C/T
polymorphism increased the CAD risk in a Chinese population
(Pei et al., 2014). In addition, in another Chinese population Zou
et al. also got the similar conclusion in 2013 (Zou et al., 2013).
On the contrary, in 2006, Koch et al. did not find any significant
genotype distributions difference of TGF-β1 gene -509C/T gene
polymorphism between control and CAD patients and they
concluded that the TGF-β1 gene -509C/T polymorphism was
not associated with CAD in a Caucasian population (Koch et al.,
2006). In 2009, Drenos got the similar negative conclusion in
another Caucasian population (Drenos et al., 2009).
In the current study, a meta-analysis involving 6,377 CAD
patients and 5,324 controls from eight separate studies was
performed (Supplement S1). The current meta-analysis will help
us further estimate the relationship of TGF-β1 gene -509C/T
polymorphism and CAD and formulate a novel individualized
therapy strategy of CAD.
MATERIALS AND METHODS
Publication Search and Inclusion Criteria
The terms as “TGF-β1,” “-509C/T,” “polymorphism” and
“coronary artery disease” were used to retrieve the electronic
databases including China Biological Medicine Database, China
National Knowledge Infrastructure, PubMed, Embase, and Web
of Science. The last research was updated on December 21, 2016
with the publication years ranging from 1996 to 2014.
The recruited studies should conform to such major criteria
as the follows: (a) Estimation of the association of TGF-β1 gene
-509C/T polymorphism and CAD. (b) CAD was diagnosed by
coronary angiography and the criteria was defined as the luminal
narrowing in at least one coronary artery was no less than 50%.
The patients with any previous history of documented CAD, with
or without coronary revascularization were also classified to be
CAD group (Li et al., 2016). The healthy population in the similar
period without coronary artery stenosis was included in the
control group. (c) The case-control or cohort studies published
officially should be included. (d) The control group genotype
member should follow the Hardy-Weinberg equilibrium (HWE).
Data Extraction
According to a standard protocol, the data was drawn out.
The meta-analysis was performed by three investigators; two of
whom were responsible for searching out the individual studies
in duplicate, and the third one was to resolve the disputes
between the two investigators. Those studies that did not meet
the major selection criteria, that were repeated publications,
or that supplied inadequate data were got rid of the present
meta-analysis. If similar data was found in different papers by
the same author group, the data was only adopted for one
time. The following items as publication year, the first author’s
name, ethnicity, country, genotyping method, matching criteria,
genotype number, and total number of cases and controls should
be listed in the data table.
Statistical Analyses
Six genetic models as the allelic (T allele distribution frequency),
recessive (TT vs. CC+CT), dominant (CC vs. TT+CT),
homozygous (TT vs. CC), heterozygous (CT vs. CC), and
additive (T vs. C) genetic models were adopted in the present
meta-analysis. The odds ratios (ORs) and their corresponding
95% confidence intervals (CIs) were used to compare the
association of TGF-β1 gene -509C/T polymorphism and CAD.
The heterogeneity among the studies was calculated by Chi-
square-based Q-tests and the significance was set at P < 0.05
level (Cochran, 1968). If heterogeneity existed among the
individual studies, the random-effect model (DerSimonian and
Laird method) would be used (Dersimonian and Laird, 2015). Or
else, the fixed-effect model was adopted (the Mantel–Haenszel
method) (Mantel and Haenszel, 1959). The pooled OR was
assessed by Z test with significance set at P < 0.05 level.
TheHWEwas evaluated by Fisher’s exact test with significance
set at P < 0.05 level. The potential publication bias was assessed
by funnel plot. The funnel plot symmetry was evaluated by using
the Egger’s linear regression test on the natural logarithm scale of
the OR with significance set at P < 0.05 level (Egger et al., 1997).
The statistical analyses were performed by using Revman 5.0 and
Stata 12.0 software (StataCorp, College Station, TX, USA).
RESULTS
Studies and Populations
All of information was abstracted from 6,377 CAD cases and
5,324 controls (Table 1) (Cambien et al., 1996; Syrris et al.,
1998; Koch et al., 2006; Crobu et al., 2008; Drenos et al., 2009;
Sudomoina et al., 2010; Zou et al., 2013; Pei et al., 2014).
Sixteen manuscripts were found out by the retrieval process,
among which eight papers conformed to the inclusion criteria.
Among the eight excluded studies, three papers were of reviews
character, and two manuscripts violated the HWE (Sie et al.,
2006; Najar et al., 2011). Three papers were not involved with
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TABLE 1 | Characteristics of the investigated studies of the association between the TGF-β1 gene -509C/T polymorphism and CAD.
Author Year Country Ethnicity Genotype CAD Control Matching criteria sample size (CAD/
control)
CC CT TT CC CT TT
Zou SM 2013 China Han PCR-LDR 49 153 138 49 128 94 Age, ethnicity,HDL-C 340/271
Pei F 2014 China Han PCR-RFLP 97 217 143 111 201 101 Age, sex, ethnicity, smoker, HP 457/413
Crobu F 2008 Italia Caucasian PCR-RFLP 67 87 47 80 92 29 Ethnicity 201/201
Koch W 2006 German Caucasian PCR-RFLP 1581 1659 417 564 508 139 Ethnicity 3657/1211
Syrris P 1998 UK Caucasian PCR-SSCP 301 284 70 124 97 23 Age, ethnicity 655/244
Cambien F 1996 FR,NIE Caucasian PCR-SSCP 240 257 66 263 297 69 Ethnicity 563/629
Sudomoina MA 2010 Russia Caucasian PCR-RFLP 77 150 37 90 103 19 Ethnicity 264/212
Drenos F 2009 England Caucasian PCR-RFLP 120 100 20 1090 885 168 Ethnicity 240/2143
CAD, coronary artery disease; HDL-C, high density lipoprotein-cholesterol; HP, hypertension; UK, United Kingdom; FR, France; NIE, Northern Ireland. PCR-LDR, Polymerase chain
reaction-ligase detection reaction; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP, Polymerase Chain Reaction-Single Strand Conformation
Polymerase; Case-control study design were adopted in the above studies.
TGF-β1 gene -509C/T polymorphism or CAD (Supplement S2).
Six countries were included in the present meta-analysis as
China, Italia, German, United Kingdom, France, and Russia.
They belong to Chinese and Caucasian subgroups respectively.
Two individual studies were included in the Chinese subgroup
and six individual studies were included in the Caucasian
subgroup.
Pooled Analyses
A significant association between TGF-β1 gene -509C/T
polymorphism and CAD was detected in the total population
under allelic (OR: 1.130, 95% CI: 1.060–1.200, P = 0.0001),
recessive (OR: 1.390, 95% CI: 1.100–1.750, P = 0.006), dominant
(OR: 0.857, 95% CI: 0.785–0.935, P= 2.507×10−4), homozygous
(OR: 1.258, 95% CI: 1.098–1.442, P = 0.001), heterozygous (OR:
1.147, 95% CI: 1.046–1.257, P = 0.003), and additive genetic
models (OR: 1.131, 95% CI: 1.063–1.204, P = 5.442× 10−5).
In the subgroup analysis, there was a significant association
between them in Chinese population under all of the genetic
models (P < 0.05), except under the heterozygous genetic model
(P >0.05).
In the Caucasian subgroup, a significant association between
themwas also detected under all of the genetic models (P< 0.05),
except under the recessive genetic model (P > 0.05).
In the subgroup analysis, there was a significant association
between them in Chinese population under allelic (OR: 1.260,
95% CI: 1.090–1.460, P = 0.005), recessive (OR: 1.800, 95%
CI: 1.400–2.330, P = 3.241 × 10−6), dominant (OR: 0.743,
95% CI: 0.577-0.957, P = 0.022), homozygous (OR: 1.561, 95%
CI: 1.164–2.092, P = 0.003), and additive genetic models (OR:
1.259, 95% CI: 1.088–1.458, P = 0.002). However, no significant
association between TGF-β1 gene -509C/T polymorphism and
CAD was found under heterozygous genetic model (OR: 1.222,
95% CI: 0.933–1.600, P = 0.146).
In the Caucasian subgroup, a significant association between
them was also detected under allelic (OR: 1.100, 95% CI: 1.030–
1.180, P = 0.002), dominant (OR: 0.873, 95% CI: 0.796-0.958,
P = 0.004), homozygous (OR: 1.187, 95% CI: 1.017–1.384,
P = 0.029), heterozygous (OR: 1.137, 95% CI: 1.031–1.254,
P = 0.010), and additive genetic models (OR: 1.105, 95% CI:
1.031–1.184, P = 0.005). However, no significant association
was detected under recessive genetic model (OR: 1.230, 95% CI:
0.970–1.560, P = 0.08) (Table 2, Figures 1–6).
There was no significant heterogeneity in the whole
population under all of the genetic models (Pheterogeneity > 0.05)
except under the recessive genetic model (Pheterogeneity < 0.05).
In the subgroup analysis stratified by ethnicity, no heterogeneity
was detected either in the Chinese subgroup or in the
Caucasian subgroup under the recessive genetic model
(Pheterogeneity > 0.05).
Bias Diagnostics
The publication bias among the individual studies was evaluated
by using the funnel plot and Egger’s test. No publication bias
was visualized in the funnel plot under the allelic genetic model
(Figure 7). Additionally, no significant difference was detected in
the Egger’s test yet, which indicated that there was no publication
bias in the current meta-analysis by using allelic genetic model
(T = 2.04, P = 0.088).
DISCUSSION
In the current meta-analysis, a significant association was
detected in the whole population between TGF-β1 gene -509C/T
polymorphism and CAD under allelic (OR: 1.130), recessive
(OR: 1.390), dominant (OR: 0.857), homozygous (OR: 1.258),
heterozygous (OR: 1.147), and additive genetic models (OR:
1.131). In the subgroup analysis by ethnicity, a significant
association in Chinese subgroup was also found under allelic
(OR: 1.260), recessive (OR: 1.800), dominant (OR: 0.743),
homozygous (OR: 1.561), and additive genetic models (OR:
1.259). A significant association was also found in the Caucasian
subgroup under allelic (OR: 1.100), recessive (OR: 1.230),
dominant (OR: 0.873), homozygous (OR: 1.187), heterozygous
(OR: 1.137), and additive genetic models (OR: 1.105). In
conclusion, it was implied that the carriers with T allele of TGF-
β1 gene -509C/T polymorphism might increase CAD risk, both
in the Chinese and Caucasian population.
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TABLE 2 | Summary of meta-analysis of association between the TGF-β1 gene -509C/T polymorphism and CAD.
Genetic model Pooled OR (95% CI) Z-value P-value Study number CAD size Control size Pheterogeneity(I2%)
Allelic genetic model 1.130 (1.060–1.200) 3.87 0.0001* 8 6377 5324 0.11 (41.0)
Chinese subgroup 1.260 (1.090–1.460) 2.83 0.005* 2 797 684 0.74 (0)
Caucasian subgroup 1.100 (1.030–1.180) 3.09 0.002* 6 5580 4640 0.10 (45.0)
Recessive genetic model 1.390 (1.100–1.750) 2.77 0.006* 8 6377 5324 0.007* (64.0)
Chinese subgroup 1.800 (1.400–2.330) 4.51 3.241 × 10−6* 2 797 684 0.75 (0)
Caucasian subgroup 1.230 (0.970–1.560) 1.75 0.08 6 5580 4640 0.08 (49.0)
Dominant genetic model 0.857 (0.785–0.935) 3.48 2.507 × 10−4* 8 6377 5324 0.190 (29.8)
Chinese subgroup 0.743 (0.577–0.957) 2.30 0.022* 2 797 684 0.884 (0)
Caucasian subgroup 0.873 (0.796–0.958) 2.87 0.004* 6 5580 4640 0.127 (41.7)
Homozygous genetic model 1.258 (1.098–1.442) 3.30 0.001* 8 6377 5324 0.130 (37.5)
Chinese subgroup 1.561 (1.164–2.092) 2.98 0.003* 2 797 684 0.749 (0)
Caucasian subgroup 1.187 (1.017–1.384) 2.18 0.029* 6 5580 4640 0.134 (40.7)
Heterozygous genetic model 1.147 (1.046–1.257) 2.92 0.003* 8 6377 5324 0.407 (2.9)
Chinese subgroup 1.222 (0.933–1.600) 1.45 0.146 2 797 684 0.909 (0)
Caucasian subgroup 1.137 (1.031–1.254) 2.58 0.010* 6 5580 4640 0.224 (28.2)
Additive genetic model 1.131 (1.063–1.204) 3.87 5.442 × 10−5* 8 6377 5324 0.108 (40.6)
Chinese subgroup 1.259 (1.088–1.458) 3.09 0.002* 2 797 684 0.744 (0)
Caucasian subgroup 1.105 (1.031–1.184) 2.83 0.005* 6 5580 4640 0.104 (45.3)
*P ≤ 0.05. CAD, coronary artery disease; CI, confidence interval; OR, odds ratio; CAD size, the total number of CAD cases; control size, the total number of control group; Allelic genetic
model, T allele distribution frequency; recessive genetic model: TT vs. CC+CT, Dominant genetic model: CC vs. TT+CT; Homozygous genetic mode, TT vs. CC; Heterozygous genetic
model, CT vs. CC; Additive genetic model, total T allele vs. total C allele.
FIGURE 1 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under an allelic genetic model (distribution of T allelic frequency
of TGF-β1 gene -509C/T polymorphism).
No significant heterogeneity was detected in the whole
population under all of the genetic models except the
recessive genetic model. Under the recessive genetic model, a
significant heterogeneity was detected in the whole population
(Pheterogeneity = 0.007). In the subsequent subgroup analysis
stratified by ethnicity, the heterogeneity did not exist any longer
in the Chinese or Caucasian subgroup (P > 0.05).
The pathogenesis of CAD include coronary atherosclerosis,
embolism, dissecting aneurysm, coronaritis, malformation
of coronary artery, metabolic disease, infection, trauma and
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FIGURE 2 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under a recessive genetic model (TT vs. CC+CT).
FIGURE 3 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under a dominant genetic model (CC vs. TT+CT).
et al, of which coronary atherosclerosis accounts for more
than 90%. Atherosclerosis is proliferative inflammatory
lesions. The pathological changes include the vascular
endothelial cells dysfunction, the vascular smooth muscle
cells (VSMCs) proliferation and migration, the extracelluar
matrix proliferation, the inflammatory cells infiltration,
the fibrous cap formation, and rupture and angiogenesis
(Yang et al., 2006).
Recently the researches about the association of some
cytokines and CAD have become the research hot, particularly
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FIGURE 4 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under a homozygous genetic model (TT vs. CC).
FIGURE 5 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under a heterozygous genetic model (CT vs. CC).
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FIGURE 6 | Forest plot of CAD associated with TGF-β1 gene -509C/T polymorphism under an additive genetic model (T vs. C).
FIGURE 7 | The funnel plot for studies of the association of CAD
associated with TGF-β1 gene -509C/T polymorphism under an allelic
genetic model (distribution of T allelic frequency of TGF-β1 gene
-509C/T polymorphism). The horizontal and vertical axis correspond to the
OR and confidence limits. OR, odds ratio, SE; standard error.
the TGF-β1. TGF-β1 is the disulfide bonded dimer which consists
of two 12.5 kDa polypeptide chains. The newly synthesized
TGF-β1 is the inactive precursor protein which is constituted
with 391 amino acid residues. The 25 kDa active TGF-β1 is
generated by the enzymolysis in vivo or disposed by acid,
urea and protease in vitro. TGF-β1 plays the multifunctional
regulation role as inhibiting the inflammatory cytokines,
regulating the cells proliferation and differentiation, embryonic
development, damage repair and angiogenesis through the
endocrine, and paracrine mechanisms (Feinberg et al., 2000).
TGF-β1 plays the important roles in the coronary
atherosclerosis. TGF-β1 could down regulate many cytokines
level and function. It can inhibit TNF-α synthesis and reduce its
effect. TGF-β1 can decrease the VCAM-1 expression induced by
the inflammatory cytokines and inhibit the leukocytes adhering
to the endothelial cells (Agassandian et al., 2015). TGF-β1 can
decrease the IFN-γ effect. TGF-β1 can reduce the macrophage
activity by decreasing the IL-1 activity (Ruscetti et al., 1992;
Gamble et al., 1993; Park et al., 2000). TGF-β1 mainly has 4 kinds
of functions. (1) TGF-β1 inhibits the VSMCs migration and
proliferation; (2) TGF-β1 induces the apoptosis of leukocytes
which participates in the vascular injury; (3) TGF-β1 reduces the
adherence of the inflammatory cells to the endothelial cells; (4)
TGF-β1 helps the vascular protection by inhibiting the human
metalloenzyme and unstability reaction in the instable plaque
(Wahl et al., 1989; Mccaffrey et al., 1999; Blobe et al., 2000).
TGF-β1 gene -509C/Tmutationmight decrease the affinity of the
promoter and transcription factor, reduce TGF-β1 transcription
level and promote the coronary atherosclerosis.
In 2012, Morris et al. performed a meta-analysis on the
association of CAD with TGF-β1 gene -509C/T polymorphism.
In this meta-analysis, they concluded that T alleles of rs1800469
in TGF-β1 were associated with complications of CAD (Morris
et al., 2012). However, only four individual studies were included.
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In 2012, Lu et al. performed another meta-analysis on the
association of CAD with TGF-β1 gene -509C/T polymorphism.
They found that T allele carriers of rs1800469 in TGF-β1 have
a 15% increased risk of CAD. In their meta-analysis, only
seven individual studies were included. Among these included
individual studies, one study by Sie deviating from the HWE was
not excluded (Lu et al., 2012). Hence, the results from the two
above meta-analysises published before were not as accurate as
that deduced from the current meta-analysis.
However, there were still some limitations in the presentmeta-
analysis. The current meta-analysis is still short of prospective
or large-scale studies on the association of TGF-β1 gene -
509C/T polymorphism and CAD. The serum TGF-β1 level was
influenced not only by the TGF-β1 gene -509C/T polymorphism,
but also by other polymorphism as -800 G/A, 868 T/C, 913 G/C,
and 11929 C/T gene polymorphism. Many other environmental
factors as age, smoke, gender, obesity, dyslipidemia, diabetes
mellitus, and hypertension might affect the CAD development.
Since these factors were not matched in most of individual
studies, it was difficult to analyze their effect on the CAD progress
(Lu et al., 2012). Additionally, according to our knowledge it is
>1000-fold confirmed association between given polymorphism
and the risk of CAD. It might not influence our every day
clinical practice concerning diagnosis or therapy yet. However,
it can help us to screen out the susceptible population for
CAD and prevent the CAD progression in advance. Therefore,
the association of TGF-β1 gene -509C/T polymorphism and
CAD is important to the prevention of CAD in the high risk
population.
As CAD is a polygenic disease, various micro-effect
genes might have an effect on the CAD risk. Other genes
polymorphisms as CD14 gene −159C/T polymorphism,
Interleukin-6 C-572G polymorphism, methylenetetrahydrofolate
reductase gene C677T polymorphism, intercellular adhesion
molecule-1 gene E469K polymorphism, ATP-binding
cassette transporter A1 gene R219K polymorphism, apo A5
gene−1131T/C, FgB−455G/A,−148C/T, and CETP gene TaqIB
polymorphisms, plasminogen activator inhibitor-1 gene 4G/5G
polymorphismmight increase the CAD risk (Li, 2012a,b; Li et al.,
2012, 2013, 2015a,b; Yanyan, 2012).
In short, TGF-β1 gene -509C/T polymorphism was
significantly associated with increased CAD risk both in
the Chinese and Caucasian population. The persons with the
T allele of TGF-β1 gene -509C/T polymorphism might be
predisposed to CAD risk. This conclusion might guide us to
establish a novel CAD individualized treatment. In consideration
of the above limitations, more researches on the association of
TGF-β1 gene -509C/T polymorphism and CAD needed to be
conducted to further confirm the conclusions in the future.
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